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Since primitive times, herbs have been extensively used in conventional remedies for boosting cognitive impairment and age-
associated memory loss. It is mentioned that medicinal plants have a variety of dynamic components, and they have become a
prominent choice for synthetic medications for the care of cognitive and associated disorders. Herbal remedies have played a
major role in the progression of medicine, and many advanced drugs have already been developed. Many studies have endorsed
practicing herbal remedies with phytoconstituents, for healing Alzheimer’s disease (AD). All the information in this article was
collated from selected research papers from online scientific databases, such as PubMed, Web of Science, and Scopus. *e aim of
this article is to convey the potential of herbal remedies for the prospect management of Alzheimer’s and related diseases. Herbal
remedies may be useful in the discovery and advancement of drugs, thus extending new leads for neurodegenerative diseases such
as AD. Nanocarriers play a significant role in delivering herbal medicaments to a specific target. *erefore, many drugs have been
described for the management of age-linked complaints such as dementia, AD, and the like. Several phytochemicals are capable of
managing AD, but their therapeutic claims are restricted due to their lower solubility and metabolism.*ese limitations of natural
therapeutics can be overcome by using a targeted nanocarrier system.*is article will provide the primitive remedies as well as the
development of herbal remedies for AD management.
Hindawi
Evidence-Based Complementary and Alternative Medicine
Volume 2021, Article ID 5578574, 19 pages
https://doi.org/10.1155/2021/5578574
1. Introduction
1.1. Features and Epidemiology of Alzheimer’s Disease.
Alzheimer’s disease (AD) is a seriously worrisome disease
for the well-being of people who have it and for their
caregivers—throughout the world—with a critical socio-
economic liability. It is a familiar type of dementia. It
represents around 60%–80% of different types of dementia
[1]. Victims of AD commonly exhibit irreversible degen-
eration and progressive loss in the neurons of the entorhinal
cortex and hippocampus along with several degrees of
cognitive functions, namely, trouble in recollecting names,
ongoing occasions, and comorbid behavioral dysfunctions,
like depression. In advanced phases, motor nerve degen-
eration occurs, like trouble in talking, gulping, and strolling,
which can inevitably prompt the passing away of the person
[1,2]. It has been assessed that worldwide there are 35million
individuals suffering fromAD and dementia and by 2030 the
figure may rise to around 65 million, and it might get
multiplied by 2050 [1, 3]. Various factors, such as decreased
physical action, infection, smoking, and occurrence of
diseases like obesity and diabetes, are a threat to the
emergence of AD [4]. *e various potential mechanisms are
blood-brain barrier (BBB) disruption [5], impaired brain
metabolism [5], cellular autophagy impairment [6], unset-
tling influence of calcium homeostasis and expanded oxi-
dative stress [7], expanded neuroinflammation [8], and
neuronal apoptosis [9], at least one of described pathologies
could be present, causing AD. Generally, patients suffer from
late-onset AD, an irregular type of AD; however, less than
1% of the prevailing cases are characterized as early-onset
AD, a genetic type of AD. Genetically linked AD is asso-
ciated with the mutated amyloid precursor protein (APP)
and/or presenilin-1 (PS-1) and presenilin-2 (PS-2) genes.
*e mutation in the PS genes is brought about by mixing
natural and hereditary variables and acknowledging poly-
morphism in the “ε4 allele” of the apolipoprotein E (APOE)
gene [10].
1.2. Pathophysiology of Alzheimer’s Disease. Major patho-
logical signs of AD include amyloid-containing senile pla-
ques amassing in the extracellular site, activation and
accumulation of the microtubule-associated protein tau-
(MAPT-) driven neurofibrillary tangles (NFTs) inside the
cell, and proximity of persistent neuronal inflammation in
the infected parts. *e various assumptions, together with
the cholinergic, amyloid, and tau assumptions (Table 1),
identify with the etiology of the disease [7, 25]. Amyloid
hypothesis is considered themost significant theory in which
irregular preparation of β-amyloid (Aβ) and/or injury of its
systemic clearance are accountable for AD growth-associ-
ated phenotypes. Aβ is produced by the action of proteolytic
enzymes, that is, β- and c-secretases on the APP, although
Aβ overproduction and/or potential impedance of its dis-
pensation may bring about its extracellular aggregation.
Indeed, surplus production of Aβ is a regular feature of a
genetically linked AD or early-onset AD, whereas the late-
onset AD is recognized by the deficiency in Aβ clearance as
opposed to its excess production [26]. In any case, such
disorganization in Aβ homeostasis triggers the formation of
the Aβ-senile plaques, which in turn irreversibly stimulate
the astrocytes and microglia. Chronic alteration in glial cell
functionality intervenes with the structural and functional
integrity of the associated neurons, leading to neuro-
degeneration and impairment of the fate of neurotrans-
mitters, which ultimately results in the development of
clinical indications of AD [27]. Additionally, NFTs are an
example of the major features of pathological AD. *e
building block proteins of the cytoskeletal and the signal
transduction pathways of neurons amassed with NFTs are
hampered drastically due to impairments in the protein
posttranslational changes, such as phosphorylation of
structural microtubule proteins and functional tubulin-as-
sociated proteins. Furthermore, MAPT, a significant com-
ponent of NFTs, is seen to be hyperstimulated in the brains
of AD patients [28]. Several kinases are involved in the
phosphorylation of the tau protein. Besides, the serine-
threonine protein kinases, namely, c-Jun N-terminal kinase
(JNK), cyclin-subordinate kinase 5 (CDK5), glycogen syn-
thase kinase 3β (GSK3β), and p38, are proline-directed,
which triggers the stimulation of the *r-Pro or Ser-Pro tau
motifs, by phosphorylating them [29], thus prompting
missorting of the tau to the somatodendritic location, which
disturbs the microtubule dynamics, along with tau poly-
merization and accumulation in its hyperphosphorylated
structure [28]. *e fibrils and tau oligomers feature as the
initiators of the inflammatory response in the microglia [30],
and the thickness of NFTs corresponds to the retardation in
cognitive abilities in a person suffering from AD [10]. Even
though Aβ is greatly considered as a pathological sign of AD
pathophysiology, numerous ongoing proposals are involved
in the dismissal of this hypothesis. However, a range of
preclinical as well as clinical interventions have failed to
prove the significance of targeting Aβ as a therapeutic
modality [2, 31], and, hence, more research is being done on
tau pathology and neuroinflammation [25], as previously
studies have rarely done any research on the link between Aβ
and tau in AD. *e ongoing pattern has included another
keyword called “neuroinflammation”; this approach is ex-
pected to have enormous scope in the etiology of AD,
unequivocally upheld by the genetic, clinical, and preclinical
examinations [4, 32]. Central nervous system (CNS) in-
flammation is recognized as neuroinflammation, which is
activated by immune cells of the brain (like astrocytes and
microglia) as well as periphery-derived immune cells (like
white blood cells), trailed by the discharge of secondary
messengers, because of certain damage nearby or as a re-
action to inflammatory components [33, 34]. Inflammatory
procedures in the brain are generally strongly controlled
when compared with the peripheral tissues [35]. In any case,
risk factors of AD, like diabetes, obesity, infections, smoking,
and decreased physical action, may offer a thrust to systemic
inflammation, leading to disruption of the BBB followed by
the progressive inflammatory response in the resident im-
mune cells of the brain [4, 36]. Although microglia, the
macrophages of the brain, are the main immune effector
cells in CNS, other kinds of cell-like oligodendrocytes,
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astrocytes, endothelial cells, and nonmicroglial myeloid cells
may take an interest in the inflammatory procedures [4, 34].
Many outcomes speculate that impairment in the immune
response may be a causative aspect in AD idiopathy [37] as
well as a reason for neuron loss and may subsequently effect
cognition and neuronal plasticity [34, 38, 39]. At the mo-
lecular level, astrocytes and microglia activate the inflam-
matory response cycle by activating the immunoregulatory
mechanisms like proinflammatory cytokines and the com-
plement system [40, 41]. Microglia has a scope for biological
functions, for example, synaptic plasticity maintenance,
synaptogenesis, CNS development, antigen presentation,
pathogen recognition, and phagocytosis [42]. *ese proin-
flammatory cytokines and associated complement systems
have a progressive and destructive impact on the brain of AD
patients. Besides, microglia keeps control to eliminate Aβ
deposits. *ese inflammatory mediators furthermore trig-
ger/stimulate the impairment in the cognition level as well as
the necrotic impact on the neuron, that is, cytotoxicity [42].
Furthermore, two types of stimulation patterns have been
exhibited by these cells: classical activation (M1 phenotype)
and alternative activation (M2 phenotype). Classical acti-
vation stimulation is portrayed by discharging TNF-α and
interleukins (IL), although another stimulation arbitrates the
anti-inflammatory effects, which favors AD [39, 42].
1.3. Current Cerapeutic Approaches for Alzheimer’s Disease
Patients. *ere was no innovative medication endorsement
for AD later in 2003 [31], and the present treatment choices
provide only symptomatic relief [32, 33]. Acetylcholinesterase
inhibitors such as galantamine, donepezil, and rivastigmine
are utilized to refine memory and consideration in AD pa-
tients assisting in expanding the intensities of acetylcholine by
forestalling its break at the synapsis. While galantamine and
rivastigmine are utilized for slight-to-modest AD, donepezil is
utilized for all phases of AD. Tacrine (TAC) is the major
prescription given for AD treatment, as an AChE inhibitor.
As it was receding from the market due to its hepatic toxicity
at prescribed dosages, it has shown an extensive margin as the
most utilized AChE inhibitor in the progress of multitarget
anti-AD drugs. Another alternative for modest-to-severe AD
which is appropriate is recognized as the N-methyl-D-
aspartate (NMDA) receptor antagonist, with slight side ef-
fects, for example, dizziness, gastrointestinal irritation, and
headache [32]. During various potential therapeutics, in-
cluding numerous disease-modifying agents, these came into
the clinical trials, and many of them are in phase III. Im-
portantly, Aducanumab, ANAVEX2-73, ALZT-OP1a/b,
CAD106, Crenezumab, and E2609 cover a fair proportion of
these developing drugs, that is, 61% of the total drugs under
phase-III trial. A majority of these therapeutic candidates aim
at amyloid-related pathologies. Be that as it may, different
targets, for example, neurotransmitter-based, tau-based, an-
tioxidant-based, and anti-inflammation-based targets, are
additionally under clinical trial. Two of these preliminaries are
focusing on inflammatory pathways and recommend neu-
roinflammation as a significant causative element for AD-
related pathophysiology [31].
Table 1: Neurological hypothesis and effect of phytoconstituents in AD.
Types of hypothesis Class Natural compounds Pharmacological/mechanism of action References
Secretase hypothesis Neuronal cells andcell-free system
Myricetin
Reduced the generation of Aβ [11]
It also decreased the production of Aβ via
upregulation of the α-secretase actions and/or
downregulation of β-secretase actions
[12]
Tannic acid
Prevention of cognitive decline, inhibition of the
activity of β-secretase, and reduction of the AD-
like pathology in transgenic mice
[13]
Aβ aggregation Biflavonoids Taiwaniaflavone andmonoflavonoid apigenin
Observed that the biflavonoid was more effective at
decreasing the extension of Aβ fibril [14]
Nontoxic Aβ oligomers Oligomers Small molecules offlavonoids
Soluble Aβ oligomers are the main toxic species of
Aβ triggering neurodegeneration; Aβ oligomers
over monomeric fibrillary Aβ are started as active
therapeutics for nullifying and pointing Aβ toxicity






Inhibiting the formation of Aβ fibril, quercetin was
less effective in terms of improving the toxicity of





kinase 3 beta (GSK-
3β)
Linarin
Prevents the neurotoxicity induced by Aβ (25–35)
via PI3K/Akt activation, which can subsequently
lead to promotion of Bcl-2 regulation and
inhibition of GSK-3β. It plays a key role in
neuroprotection and AChE inhibition
[19]
Oxidative stress Biflavonoid Morelloflavone Potential to act as a potent inhibitor of lipidperoxidation [20]
Natural flavonoid Silybum marianum Promotes the viability of neuron upon hydrogenperoxide insult [21, 22]
RAGE Polyphenols Camellia sinensis RAGE plays a role as inducer of oxidative stress(OS) and AD pathophysiology [23, 24]
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2. Medicinal Plants against Alzheimer’s Disease
A detailed description of various classes of plants utilized in
AD therapy is given below (Table 2).
2.1. Ashwagandha (Withania somnifera (L.) Dunal
(Solanaceae)). Ashwagandha belongs to the family of Sol-
anaceae and generally its root is utilized for medicinal
purposes. It is ordered as a Rasayana (rejuvenating) and is
accepted to have cell reinforcement movement, free radical
rummaging action, and a capacity to bolster a solid resistant
framework [74, 75]. *e alkaloid-rich fraction of the
Withania root showed soothing action on the CNS of many
mammals, specifying its role to create relaxation. *e
withanamides consisted of glucose and serotonin, and the
long-chain hydroxyl fatty acid moieties have been seen to
scavenge unobstructed radicals produced through the
commencement and advancement of AD. It was also ob-
served that withanamides obstructed the activated neuronal
cell death by amyloid plaques [73, 76–78].*e Ashwagandha
aqueous extract was found to improve the cholinergic action,
which helped to stimulate the acetylcholine amount and
choline acetyltransferase activity in mice, whichmight be the
perception of enhancing memory activity [79, 80]. Ash-
wagandha methanol extract was found to trigger the growth
and development of the neuronal network in human neu-
roblastoma cells [79, 81]. Sehgal et al. described that per-oral
intake of Withania root extract overturned behavioral
shortages and Aβ plaque formation in validated AD mice.
Such effects of Ashwagandha were associated with the
upregulation of the low-density lipoprotein receptor-linked
protein in the liver [82]. *e roots of Ashwagandha advance
the defense mechanism of the body in case of chronic
disease, by boosting cellular immunity along with neutral-
izing the lethal mediators of the cytotoxic cascade, namely,
cytokines and reactive oxygen species (ROS) [83, 84].
2.2. Brahmi (Bacopamonnieri (L.)Wettst. (Scrophulariaceae)).
It is an unpleasant tasting creeper plant, generally utilized in
Ayurveda as a nerve tonic, for insomnia and so many ail-
ments [85, 86]. Brahmi (family: Scrophulariaceae) contains
several branches with reduced oblong leaves and purple
flowers. Its main constituents are saponins and triterpenoid
bacosaponins (Figure 1). Bacopa monnieri (BM) acts by
lowering the activity of divalent metals, sifting ROS, re-
ducing lipid peroxides formation, and obstructing lip-
oxygenase movement [87]. It is traditionally employed for
regulating memory and cognitive function and improving
neuropharmacological and nootropic activities [88–91].
*ey secure cortical, hippocampal, and striatal neurons from
the DNA-linked dysfunctions and associated neurotoxicity
in AD. Bacopa monnieri has been also reported to decrease
cholinergic deterioration and cognition-improving actions
in rats experimentally induced with AD-like features [92].
2.3. Turmeric (Curcuma longa L. (Zingiberaceae)).
Curcuma longa (family: Zingiberaceae) improves detoxifi-
cation of the liver, regulates cholesterol level, excites the
metabolic process, and improves immunity. Turmeric is
used as an alimentary spice, where symptoms of AD are
reported, 4.4-fold less than other regions in Southeast Asian
countries [93]. *e active component of turmeric is its oil
and water-soluble curcuminoids comprising curcumin [94].
Curcumin is the primary curcuminoid, containing 3-
methoxy-4-hydroxy substituents and two feruloyl moieties.
Its terminal side units are joined by an unsaturated seven-
carbon bond that attaches a β-diketo function, which results
in a symmetric curcumin molecule. Curcumin occurs in two
probable tautomeric forms, enol and diketo, based on the pH
(Figure 1) [95, 96].
2.4. Shankhpushpi (Convolvulus prostratus Forssk.
(Convolvulaceae)). Shankhpushpi is employed as a nervine
stimulant for upgrading memory and cerebral function in
different formulae in India [85, 97, 98]. Shankhpushpi
metabolites provide nootropic and memory stimulating
action, together with improving the pharmacological
function [99]. Ethanol extract of CP and its fractions (ethyl
acetate and aqueous) notably enhance learning and memory
in rats [100]. Many studies show that administration of CP
extracts enhances the memory in aged mice and improves
the retention and spatial learning performance, demon-
strating memory-upgrading in neonatal rat pups.
2.5. Gotu Kola (Centella asiatica (L.) Urban (Apiaceae)).
Gotu Kola, commonly named Brahmi, belongs to the family
Apiaceae. *e principal constituents of Gotu Kola are sa-
ponins (asiaticosides). It is commonly used to purify the
blood, enhance memory, reduce blood pressure, and pro-
mote life. Gotu Kola helps calm the mind and dismiss
tension. In Ayurveda, Gotu Kola aqueous extracts are ap-
plied for rejuvenating and restoring neural cells and to
improve insomnia [101]. By-products from Gotu Kola
(asiatic acid and asiaticoside) are potent antioxidant com-
pounds and prevent ROS-induced neuronal death. Fur-
thermore, in vitro findings suggest that Gotu Kola is efficient
in hindering the β-amyloid cell; thus, it is effective in the
management of poison from β-amyloid in AD patients [102].
2.6. Guggulu (Commiphora). Guggulu is an oleogum resin
oozing from splits, gaps, or cuts from the bark of many plant
species, such as Commiphora mukul (Hook. ex Stocks) Engl.
(Burseraceae), Commiphora myrrha (T.Nees) Engl. (Bur-
seraceae), Commiphora kua (R.Br. ex Royle) Vollesen
(Burseraceae), and Commiphora wightii (Arn.) Bhandari
(Burseraceae). It is light yellow or earthy colored having a
sweet-smelling scent and harsh astringent taste. It consists of
a blend of 30% to 65% water-soluble gum, 25% to 40%
alcohol-soluble resins, and approximately 8% volatile oils,
water-soluble components, plus mucilage, protein, and
sugar. Alcohol-soluble excipients are commiphoric acids,
heerabomyrrhols, and commiphorinic acid. It also contains
phenols, ferulic acid, and nonphenolic aromatic acids, which
are effective antioxidants, and they are valuable for AD
[103–105].
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2.7. Jyotishmati (Celastrus paniculatusWilld. (Celastraceae)).
Jyotishmati is a significant plant valued for its quality,
which can be improved for a long time. It is employed for
enhancing memory and maintaining cerebral activities
[106]. Celastrus paniculatus (CP) extricates secured neu-
ronal cells against H2O2--actuated poison to some extent
Table 2: Medicinal plants against AD.
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because of their cancer prevention activity and capacity to
activate antioxidant proteins. Celastrus paniculatus also
extracts secured neuronal cells from glutamate-induced
toxicity, by controlling the glutamate receptor activities.
*e cholinergic activity of CP seed aqueous extract was
observed in a dose-dependent manner thereafter, refining
memory activity [107].
2.8. Jatamansi (Nardostachys jatamansi (D. Don) DC.
(Caprifoliaceae)). Jatamansi is a very rich plant that is used
in medicine, and it is respected in Ayurveda. *e principal
part of the Nardostachys jatamansi (NJ) is the rhizome or
root, which has therapeutic value. It contains different types
of coumarins and sesquiterpenes. NJ extract showed a de-
crease in the signs of chronic fatigue syndrome in rats. *e
alcoholic extract of Nardostachys jatamansi showed signif-
icant improvement in the learning and memory of both
young and aged mice [108].
2.9.Ginkgo (GinkgobilobaL. (Ginkgoaceae)). *e leaf extract
of Ginkgo biloba is an extensively used medicinal plant,
which belongs to the Ginkgoaceae family. *e primary
phytoconstituents of ginkgo are comprised of terpenoids
and flavonol glycosides. Its leaf extract is commonly used for
age-related memory disorders in several European and
Asian countries [109]. G. biloba extract is extensively
employed for treating patients with numerous forms of
dementia in Europe [110, 111]. G. biloba nanosized extract
improves acetylcholine neurotransmitter discharge from
several sections of the brain compared to control group
animals. Its nanosized extract shows enhanced bioavail-
ability and a superior immersion level [112]. *e preclinical
experiment concludes that ginkgo reduces the oxygen
radical release and proinflammatory purpose of macro-
phages and decreases the corticosteroid creation and pro-
liferation, glucose uptake and utilization, and adenosine
triphosphate (ATP) production [113]. Ginkgo also seems to































































Structure of miscellaneous compounds
Figure 1: Structure of some active compounds against AD.
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deformability and reducing red cell accumulation, encour-
aging nitric oxide production, and alienating platelet-acti-
vating factor receptors [113].
3. Phytoconstituents against
Alzheimer’s Disease
A detailed description of various phytoconstituents reported
for the cure of AD is given below (Figure 2).
Baicalein (1) is a potent antioxidant obtained from
Scutellaria baicalensis Georgi (Lamiaceae), which is
employed in Traditional ChineseMedicine (TMC). Baicalein
showsmore powerful anti-BACE1 activity [IC50 � µM]when
compared with quercetin and luteolin [114]. Baicalein has
been also reported to cause Aβ-oligomerization and fibril-
lation and inhibition of Aβ-induced toxicity in PC12 cells
and disaggregation of preformed Aβ amyloid fibrils [115].
Baicalein oral intake decreases the BACE1 protein level [116]
and also its continual use improves Aβ deposition in both
the N2a-Swedish APP cells and the neuronal cell group.
Moreover, it exhibits BACE1-reducing activity (IC50 of
50 µM) [11, 117]. Quercetin has been found to reduce
BACE1 expression in medicated male C57BL/6 strain mice
and, thus, negatively controls the amyloidogenic treating of
βAPP [118].
Myricetin (3) polyphenolic compound, also referred to
as hydroxyquercetin, shows neuroprotective effects against
neuronal cell injury tempted by Aβ [119]. *e hydrophobic
nature and low molecular weight of myricetin enhance the
crossing of BBB, which provides an excellent therapeutic
environment [120]. Shimmyo et al. [119] have pointed out
that myricetin has a dual role, which reduces BACE1 activity
(IC50 � 2.8 µM), exclusive of affecting protein expression,
and activates the α-secretase (ADAM10) in the cell-free
enzyme activity. *e outcome of myricetin on neuronal cells
has been found to be lower than anticipated.
Genistein (4) reduced the BACE1 action in a dose-
dependent manner (IC50 � 6.3 µM). Genistein also reduced
Aβ-induced inflammation and cell death in in vivo and cell-
based studies [121–123]. Another study indicated that a
lower concentration of genistein crossed the BBB without
affecting neurotoxicity [124].
Salvianolic acid (Sal B) (5) is a derivative of caffeic acid,
obtained from the Salvia miltiorrhiza Bunge (Lamiaceae)
root, found to disaggregate preformed fibrils in a minimized
Aβ fibril formation. Sal B also modulates BACE1 activity in
SH-SY5Y-APPsw and decreases Aβ production in H4-
SwedAPP, N2a-SwedAPP, and HEK-BACE1 cells [125–127].
Ferulic acid (6) obtained fromOryza sativa L. (Poaceae),
Triticum aestivum L. (Poaceae), and other fruits and vege-
tables has been seen to reduce the Aβ groups at a con-
centration of 1.57 µM in in vivo and in vitro studies [128].
Ferulic acid also reduces the BACE1 enzymatic action and
points to BACE1 stability, affecting mRNA expression
level [129].
Oral intake of tannic acid (7) at 30mg/kg/day dosage in
transgenic PSAPP mice enhances the diminishing behavior,
decreases cerebral amyloidosis, and enhances anti-
amyloidogenic βAPP processing without exhibiting any side
effects [13].
Berberine (8) is an isoquinoline alkaloid, isolated from
Coptis chinensis Franch. (Ranunculaceae), having neuro-
pharmacological properties, which regulate βAPP process-
ing, resulting in a decline of the Aβ protein. Berberine is
administered orally at a dosage of 25 or 100mg/kg per day in
transgenic AD mice, for four months, which indicates
considerable mitigation of Aβ pathology and lack of
influencing BACE1 protein levels [130].
Epiberberine and Groenlandicine (9 and 10) are
protoberberine alkaloids that inhibit BACE1 activity with
IC50 values of 8.55 and 19.68 µM, respectively [131].
2,2,4-Trihydroxychalcone acid (TDC) (11), a derivative
of Chalcone-flavanoids, isolated from Glycyrrhiza glabra
L. (Fabaceae), reduces BACE1 activity (Ki value� 3.08 µM;
IC50 � 2.5 µM). TDC reduces production of the Aβ40 and
Aβ42 stages in the HEK293-APPswe cells by efficiently
overcoming the BACE1 activity on the βAPP. TDC does not
exhibit any impact on α- and c-secretases, effectively im-
pedes Aβ in cells by restraining BACE1 activity, and does not
affect any BACE1 protein levels in cell-based assays and in
vivo (B6C3-Tg mice) studies [132].
Cardamonin (12) isolated from the Boesenbergia ro-
tunda (L.) Mansf. (Zingiberaceae) shows potent inhibition
(IC50 � 4.35± 0.38 µM) and does not alter the TACE
(α-secretase). In silico studies with −9.5 kcal/mol results
indicates its affinity to strongly bind with enzymes and it has
been verified to cross the BBB easily [133]. Oral intake of
cardamonin for 30 weeks at a dose of 10mg/kg does not
show any superficial toxicity, thus acknowledging its safe
consumption [134].
Ginsenosides (13), a phytoconstituent of Panax ginseng
C.A.Mey. (Araliaceae), show a decrease in BACE1 activity.
Ginsenosides are reported to decrease BACE1 activity and
BACE1 expression, without any action on the total APP and
sAPPα levels in in vitro testing [135].
Asperterpenes A and B (14 and 15)meroterpenoids are
obtained from Aspergillus terreus *om. and soil-derived
mold. *ey show strong BACE1 inhibitory actions in HEK-
BACE1 cells. *e IC50 values of asperterpenes A and B are
found to be 78 and 59 nM, respectively. Asperterpene A
(70 nM) lowers Aβ42 development and prevents BACE1
action in the HEK-293 and N2a-APP cell lines [136].
Rutin and Galangin (16 and 17) are extracted from
Fagopyrum esculentumMoench (Polygonaceae) and Alpinia
officinarum Hance (Zingiberaceae) and, hence, act as βAPP-
selective BACE1 inhibitors and show a capacity to unsta-
bilize BACE1 division [137].
Andrographolide (18) is a labdane diterpenoid
extracted from Andrographis paniculata (Burm. F.) Nees














































































































































































Figure 2: Phytoconstituents against AD
Evidence-Based Complementary and Alternative Medicine 9
(Acanthaceae). It shows the inhibiting property against
glycogen synthase kinase-3β (GSK-3β) as well as reduction
of the phosphorylated tau protein and amyloid-beta ag-
gregate maturation in aged degus [138–140].
4. Nanocarrier Containing Natural Product
Used to Combat Alzheimer’s Disease
In today’s scientific community, the main challenge is to
deliver a drug to its specific site. Nanocarriers play a very
important role in delivering the medicaments to any target
specifically (Figure 3). Several drugs have been reported for
the management of age-linked complaints such as dementia,
AD, and the like. Toxicity and safety are the major limita-
tions associated with the use of synthetic drugs; thus sci-
entists are focusing on the practice of natural bioactive AD
management. Many phytochemicals are capable of man-
aging AD, but their therapeutic claims are restricted due to
their lower solubility and metabolism, caused by their large
molecular size. *ese limitations of natural therapeutics can
be overcome by using a targeted nanocarrier system.
4.1. Curcumin. Curcumin is a polyphenol compound re-
ported for its neuroprotective property, having good action
against neurological disorders. Mulik et al. developed
apolipoprotein E3-mediated poly(butyl) cyanoacrylate NPs
containing curcumin, which showed higher cellular uptake
and phosphatability by its sustained release behavior [141].
Tiwari et al. developed a nanoparticle of curcumin-loaded
poly(lactic-co-glycolic acid) (PLGA), which showed activity
toward the induction of neurogenesis, by internalization
into the hippocampus neuronal stem cell [142]. *ey also
enhanced the gene expression involved in cell proliferation
and neuronal differentiation in comparison to pure cur-
cumin. *is study also revealed that curcumin nanoparticles
increased neuronal differentiation by activating the Wnt/
β-catenin pathway, involved in the regulation of neuro-
genesis. Furthermore, Mathew et al. prepared curcumin-
loaded PLGA nanoparticles and coupled them with a Tet-1
peptide, which had a retrograde transportation ability, so
that it easily penetrated the BBB and the prepared formu-
lation that destroyed the β-amyloid aggregates and also
showed its antioxidative property with a nontoxic effect
[143]. Encapsulation of curcumin within the PLGA showed
the indestructible inherent property of curcumin. Cheng
et al. prepared nanocurcumin with PLGA-loaded micelles of
average size of 80 nm, which showed improved bioavail-
ability in the brain of Tg2576 mice in comparison to pure
curcumin. It also showed a good effect in the treatment of
ADs. *ey have almost 100 percent entrapment efficiency,
with 37.6% loading of curcumin [144]. Malvajerd et al. did a
relative study of a nanolipid carrier (NLC) and solid lipid
nanoparticle (SLN), and the results revealed a high brain
uptake and bioavailability of NLC with Cmax of 390.3 ng/g,
AUC of 505.76 ng/g h, and Tmax of 1 h of the curcumin [145].
Mourtas et al. prepared a lipid-polyethylene glycol poly-
lactide PEG-curcumin derivative, which reduced Aβ ag-
gregation and enhanced penetration of curcumin in a
postmortem patient sample [146]. Zhao et al. developed
curcumin-conjugated carboxybetaine methacrylate nano-
particles, which were found to be effective against Aβ42 fi-
brils in comparison to pure curcumin [147]. Huo et al.
developed the selenium nanosphere and curcumin sele-
nium-PLGA nanosphere and they found that the result was
in favor of the curcumin selenium-PLGA nanosphere, as
compared to the selenium nanosphere in the ADmicemodel
[148]. Kakkar and Kaur 2011 prepared curcumin-loaded
solid lipid nanoparticles and they reported a neuroprotective
effect against the aluminum-induced mice brain, with al-
teration in behavioral, histopathological, and biochemical
parameters [149]. Hoppe et al. prepared a curcumin-loaded
lipid core nanocapsule, which was observed to produce
reduction in the hyperphosphorylation of tau and Aβ in
ADs, when compared with pure curcumin [150]. Meng et al.
prepared a curcumin-loaded low-density lipoprotein mimic
nanostructure, with lactoferrin. It was administered to ADs
animals, and a drastic change was noticed in ADs pro-
gression, with increased concentration in the brain and
higher bioavailability [151].
4.2. Epigallocatechin-Gallate. Many treatments show
symptomatic relief with numerous side effects in ADs, but
none can halt their development. So, for targeting a broader
target, not only the symptom but also the pathology with less
side effects, a green tea polyphenol-derived active constit-
uent epigallocatechin-gallate (EGCG), has given a lot of
hope and acted as a potential agent for therapeutic appli-
cation. Singh et al. (2018) prepared an EGCG nanoparticle
and studied the neurobehavior and pathophysiology of the
aluminum chloride-induced rat model [152]. *e results
showed that neurobehavioral impairment was significantly
increased and neuritic plaque and neurofibrillary tangles
were absent, and a lower level of biochemical immuno-
histochemical protein was found, which was the major cause
for the induction of ADs. Cano et al. developed a nano-
particle-containing EGCG and ascorbic acid and found
enhanced stability when the EGCG and ascorbic acid
nanoparticle was administered orally to the mice model, and
also the resultant EGCG accumulation in the organ, in-
cluding the brain, was higher. It was found to be five times
more concentrated than free EGCG in the long term, from 5
to 25 hours [153].*e knownmodel APPswe/PS1dE9 (APP/
PS1) mice were used in the study and it was also observed
that there was a remarkable increase in synapses and de-
crease in the burden of amyloid β plaque. Hoyos-Ceballos
et al. prepared EGCG loaded PLGA/PF127 nanoparticle,
nearly 100 nm in size, with an encapsulation efficiency of
86%. *e finding on the oxidative stress model showed
rotenone-induced ROS generation prevention and mito-
chondrial membrane potential loss, with DNA fragmenta-
tion in the nerve cells [154]. Hence, all observations
supported that EGCG had great therapeutic efficacy toward
ADs. Smith et al. prepared EGCG-containing lipid nano-
particle that was delivered to the mouse model, and they
observed good ability to promote the amyloid precursor
protein by α-secretase upregulation, which resulted in
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inhibition of β-amyloid plaque formation [155]. *e bio-
availability of nano-EGCGwas found to be two times greater
than free EGCG, and neuronal α-secretase increment was up
to 91%. Zhang et al. prepared the selenium-containing
EGCG covered by a Tet-1 peptide; it decreased EGCG cy-
totoxicity and inhibited Aβ fibrillation, with disaggregation
of the Aβ fibrils into nontoxic compounds [156].
4.3. Berberine. Berberine is an isoquinoline alkaloid that
shows a neuroprotective effect and it is used for the man-
agement of different age-related neurological disorders like
dementia, ADs, mental depression, schizophrenia, and
anxiety. *e major mechanism of berberine to treat ADs is
inhibition of acetylcholinesterase and indoleamine 2,3-
dioxygenase. In 2017, Lohan and coworkers prepared ber-
berine containing multiwalled carbon nanotubes, having a
surface coating of polysorbate and phospholipid [157]. *e
size of the prepared formulation was 186 nm with an ab-
sorption capacity of 68.6%. *ey obtained a significant
improvement of drug absorption in plasma and brain tissue
of the rat vis-à-vis a pure drug. Enhanced recovery was
observed in the memory performance of rats on days 18–20.
A good reduction in the β-amyloid plaque was noticed.
Soudi et al. synthesized surface-modified berberine chitosan
nanoparticles modified with the tween 80, PEG4000, and
miltefosine against lipopolysaccharide [158]. *e synthe-
sized formulation showed the neuroprotective behavior
against lipopolysaccharide-activated cerebral and associated
liver changes in rats.
4.4. Quercetin. It is a flavonoid, having a neuroprotective
effect with potency toward scavenging ROS, as well as some
drawbacks, like lesser solubility and lower bioavailability.
Kumar et al. prepared a Que-loaded nanolipid carrier de-
livered to the brain, which enhanced bioavailability and
antioxidant activity [159]. Quercetin- (Que-) solid lipid
nanoparticles were delivered for the aluminum-induced
neurotoxicity, and a significant betterment in memory re-
tention was observed in animal models of ADs [160]. Kuo
et al. prepared ApoE-Que-RA-PA liposome, with intended
transport via the BBB, for recovery of neurotoxicity of ADS
model. *is formulation also minimized acetylcholinester-
ase activity and Aβ plaque formation in vivo [161]. Pha-
chonpai et al. developed Que liposomes for nasal delivery.
*e study reported lowering of cholinergic neurons by a
drop in oxidative stress in the AD model [162]. Aluani et al.
studied the nanoencapsulated Que, which showed neuro-
protective behavior when compared with free Que, in the
neuronal model of oxidative stress injury [163].
4.5. Resveratrol. It is a polyphenolic agent from the stilbene
compound, which has low bioavailability and poor solubility
in water and is very fast. Frozza et al. reported a Resveratrol-
loaded lipid nanocarrier, which modulated in vitro initiation
of Aβ inflammation [164]. In another study in 2013, Frozza
et al. prepared Resveratrol LNC, which showed destruction
in Aβ1–42 in a rat model [165]. Sun et al. formulated
Resveratrol-loaded mesoporous nanoselenium, which af-
fected memory impairment and also inhibited Aβ aggregates
Curcumin + poly(butyl) cyanoacrylate NPs
Higher cellular uptake
Selenium
 containing EGCG coated
with Tet-1 peptide
Inhibited Aβ fibrillation
Berberine + multiwalled carbon nanotube































Figure 3: Delivery of herbal nanoformulation and its effects.
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and oxidative stress [166]. Similarly, Lu et al. established the
polymeric micelles loaded with Resveratrol, which inhibited
Aβ-induced damage of cells by oxidative stress [167].
4.6. Piperine. It is an alkaloid obtained from piper species
fruits which especially acts on the central nervous system
and is specifically evident on acetylcholine. Low bioavail-
ability, high lipophilic potential, and poor aqueous solubility
make Piperine different from others. Elnaggar et al. prepared
monoolein cubosome-loaded Piperine, modified it with
tween, and administered it to the ADs model, which showed
remarkable efficacy and restored cognitive function in
comparison to the free drug [168]. Etman et al. prepared
microemulsion containing Piperine and achieved high
therapeutic efficacy, with higher brain delivery in ADs
model, compared to free Piperine [169]. Yusuf et al. prepared
Piperine-loaded SLNs coated with PS80, which decreased the
SOD level, with enhanced acetylcholinesterase and reduced
plaques and tangles, while studying the histopathology [170].
*ere are multiple nanocarriers used to treat Alzheimer’s
disease. *ese nanocarriers incorporate active medicament,
either herbal or synthetic, which act on different hypotheses
causing Alzheimer’s, such as, tau protein, β-amyloid, and
oxidative stress.
4.7. Polymeric Micelles. *ey are specially designed to
prevent the hydrophobic nature of the AD drug. Kulkarni
et al. established a brain-targeting nanopolymeric structure
employing polymeric n-butyl-2-cyanoacrylate (PBCA) and
encapsulating the radio-labeled amyloid affinity drug
I-clioquinol [171]. *e loaded NPs excellently crossed the
BBB in a mouse model and improved the brain retention of
I-CQ-PBCA NPs. Chitosan-covered PLGA nanoparticles
(NPs) conjugated with a novel anti-Aβ antibody were
prepared by Jaruszewski et al., which displayed boosted BBB
uptake and better targeting of the Aβ proteins in vitro. Due
to its enhanced spreadability and stability, there is a pos-
sibility to develop a nanocarrier for analysis and cure of AD
[172].
4.8. Liposomes. *ese are developed to enhance the bio-
availability of drugs, increase their solubility, lower their
toxicity, and so forth. Mourtas et al. premeditated diverse
liposomes, incorporating a derivative of curcumin and anti-
transferrin antibody (TrF) as a BBB transport mediator.
Liposomes containing curcumin derivatives and/or anti-TrF
displayed elevated affinities for amyloid deposits in AD
patient’s brain samples [146].
4.9. Cubosomes. *ey are constricted with biodegradable
carriers with liquid crystalline structures. *ey contain a
three-dimensional structure with two aqueous phases,
within which bioactive ingredients are incorporated.
Elnaggar et al. prepared tween-integrated monoolein
cubosomes (T-cubs) enveloped with Piperine and studied
their capabilities on the AD brain. Preclinical investigation
in rats proved its effectiveness in improving cognitive skills
and delaying the progression of AD [168].
4.10. Lipid Nanoparticles. *ey are designed to combat the
drawbacks of the other developed nanocarrier systems. *is
type of particle shows a good release pattern with stability.
Bernardi et al. reported the effectiveness of indomethacin-
loaded lipid-core nanocapsules (IndOH-LNCs) to prevent
the neuroinflammatory and neurotoxic effect of Aβ1-42 on
the neuronal cells, possibly via the enhanced release of
endogenous anti-inflammatory cytokines, that is, interleu-
kin-10 and condensed glial activation and c-Jun N-terminal
kinase phosphorylation [173].
5. Conclusion
Herbal remedies have long been used for the management of
AD in the form of extracts, phytoconstituents, and their
nanocarriers. *ese have appeared as capable candidates for
the cure of AD and other related disorders. It might be
proved that botanicals are a prosperous resource of a newer
class of bioactive materials for the controlling of neurode-
generative illnesses. *e therapeutic efficacy of Withania,
Bacopa, Curcuma, andMucuna pruriens (L.) DC. (Fabaceae)
is not only limited to AD but also beneficial for the treatment
of Parkinson’s disease (PD). Withania, Bacopa, Curcuma,
and Mucuna pruriens exhibit potent therapeutic potential in
PD [174–179]. Furthermore, the in vivo activity is yet to be
revealed in animals as well as humanmodels to validate their
curative effectiveness in AD and other associated ailments. It
is expected that herbal remedies have the scope for devel-
oping some novel compounds in the drug development
process for AD management. *is current article focuses on
the types of neurological hypotheses for AD and the role of
herbal remedies to manage it.
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and M. J. Alcaraz, “Morelloflavone, a novel biflavonoid
inhibitor of human secretory phospholipase A2 with anti-
inflammatory activity,” Biochemical Pharmacology, vol. 53,
no. 5, pp. 733–740, 1997.
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